{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,25]],"date-time":"2026-10-25T20:23:11Z","timestamp":1792959791793,"version":"4.5.0"},"reference-count":55,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2023,9,14]]},"DOI":"10.7759\/cureus.45231","type":"journal-article","created":{"date-parts":[[2023,9,14]],"date-time":"2023-09-14T15:38:50Z","timestamp":1694705930000},"source":"Crossref","is-referenced-by-count":9,"title":["The Lasting Effects of COVID-19 on the Progression of Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD)"],"prefix":"10.7759","author":[{"given":"Sean","family":"Backer","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Deepesh","family":"Khanna","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.7759\/cureus.22491","article-title":"Socioeconomic determinants of COVID-19 incidence and mortality in Florida","volume":"14","author":"Backer S","year":"2022","unstructured":"Backer S, Rezene A, Kahar P, Khanna D. Socioeconomic determinants of COVID-19 incidence and mortality in Florida. Cureus. 2022, 14:e22491. 10.7759\/cureus.22491","journal-title":"Cureus"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.1007\/s42399-021-00915-2","article-title":"Covid-19 and pregnancy: risk, symptoms, diagnosis, and treatment","volume":"3","author":"Hapshy V","year":"2021","unstructured":"Hapshy V, Aziz D, Kahar P, Khanna D, Johnson KE, Parmar MS. Covid-19 and pregnancy: risk, symptoms, diagnosis, and treatment. SN Compr Clin Med. 2021, 3:1477-83. 10.1007\/s42399-021-00915-2","journal-title":"SN Compr Clin Med"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.1080\/21645515.2021.2002083","article-title":"A comprehensive review of SARS-CoV-2 vaccines: Pfizer, Moderna & Johnson & Johnson","volume":"18","author":"Patel R","year":"2022","unstructured":"Patel R, Kaki M, Potluri VS, Kahar P, Khanna D. A comprehensive review of SARS-CoV-2 vaccines: Pfizer, Moderna & Johnson & Johnson. Hum Vaccin Immunother. 2022, 18:2002083. 10.1080\/21645515.2021.2002083","journal-title":"Hum Vaccin Immunother"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.7759\/cureus.33740","article-title":"The role of Vitamin C in human immunity and its treatment potential against COVID-19: a review article","volume":"15","author":"Moore A","year":"2023","unstructured":"Moore A, Khanna D. The role of Vitamin C in human immunity and its treatment potential against COVID-19: a review article. Cureus. 2023, 15:e33740. 10.7759\/cureus.33740","journal-title":"Cureus"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.7759\/cureus.28530","article-title":"Laboratory and point-of-care testing for COVID- 19: a review of recent developments","volume":"14","author":"Kalia R","year":"2022","unstructured":"Kalia R, Kaila R, Kahar P, Khanna D. Laboratory and point-of-care testing for COVID- 19: a review of recent developments. Cureus. 2022, 14:e28530. 10.7759\/cureus.28530","journal-title":"Cureus"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.7759\/cureus.30555","article-title":"Effects of COVID-19 on pregnant women and newborns: a review","volume":"14","author":"Patel BM","year":"2022","unstructured":"Patel BM, Khanna D, Khanna S, Hapshy V, Khanna P, Kahar P, Parmar MS. Effects of COVID-19 on pregnant women and newborns: a review. Cureus. 2022, 14:e30555. 10.7759\/cureus.30555","journal-title":"Cureus"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.14218\/JCTH.2020.00140","article-title":"COVID-19 and indirect liver injury: a narrative synthesis of the evidence","volume":"9","author":"Idalsoaga F","year":"2021","unstructured":"Idalsoaga F, Ayares G, Arab JP, D\u00edaz LA. COVID-19 and indirect liver injury: a narrative synthesis of the evidence. J Clin Transl Hepatol. 2021, 9:760-8. 10.14218\/JCTH.2020.00140","journal-title":"J Clin Transl Hepatol"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.7759\/cureus.32437","article-title":"A survey of public health failures during COVID-19","volume":"14","author":"Dominquez BC","year":"2022","unstructured":"Dominquez BC, Hernandez A, Fernandez-Pacheco A, Taylor L, Kahar P, Khanna D. A survey of public health failures during COVID-19. Cureus. 2022, 14:e32437. 10.7759\/cureus.32437","journal-title":"Cureus"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.7759\/cureus.27438","article-title":"A review of COVID-19 in relation to metabolic syndrome: obesity, hypertension, diabetes, and dyslipidemia","volume":"14","author":"Makhoul E","year":"2022","unstructured":"Makhoul E, Aklinski JL, Miller J, et al.. A review of COVID-19 in relation to metabolic syndrome: obesity, hypertension, diabetes, and dyslipidemia. Cureus. 2022, 14:e27438. 10.7759\/cureus.27438","journal-title":"Cureus"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.1111\/eci.13338","article-title":"COVID-19 and non-alcoholic fatty liver disease: two intersecting pandemics","volume":"50","author":"Portincasa P","year":"2020","unstructured":"Portincasa P, Krawczyk M, Smyk W, Lammert F, Di Ciaula A. COVID-19 and non-alcoholic fatty liver disease: two intersecting pandemics. Eur J Clin Invest. 2020, 50:e13338. 10.1111\/eci.13338","journal-title":"Eur J Clin Invest"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.1111\/liv.14730","article-title":"Pathophysiological mechanisms of liver injury in COVID-19","volume":"41","author":"Nardo AD","year":"2021","unstructured":"Nardo AD, Schneeweiss-Gleixner M, Bakail M, Dixon ED, Lax SF, Trauner M. Pathophysiological mechanisms of liver injury in COVID-19. Liver Int. 2021, 41:20-32. 10.1111\/liv.14730","journal-title":"Liver Int"},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2020.03.044","article-title":"Non-alcoholic fatty liver diseases in patients with COVID-19: a\u00a0retrospective study","volume":"73","author":"Ji D","year":"2020","unstructured":"Ji D, Qin E, Xu J, Zhang D, Cheng G, Wang Y, Lau G. Non-alcoholic fatty liver diseases in patients with COVID-19: a\u00a0retrospective study. J Hepatol. 2020, 73:451-3. 10.1016\/j.jhep.2020.03.044","journal-title":"J Hepatol"},{"key":"ref13","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(20)32511-3","article-title":"Non-alcoholic fatty liver disease","volume":"397","author":"Powell EE","year":"2021","unstructured":"Powell EE, Wong VW, Rinella M. Non-alcoholic fatty liver disease. Lancet. 2021, 397:2212-24. 10.1016\/S0140-6736(20)32511-3","journal-title":"Lancet"},{"key":"ref14","doi-asserted-by":"publisher","DOI":"10.3390\/ijms20020395","article-title":"Gut-Liver axis, gut microbiota, and its modulation in the management of liver diseases: a review of the literature","volume":"20","author":"Milosevic I","year":"2019","unstructured":"Milosevic I, Vujovic A, Barac A, et al.. Gut-Liver axis, gut microbiota, and its modulation in the management of liver diseases: a review of the literature. Int J Mol Sci. 2019, 20:395. 10.3390\/ijms20020395","journal-title":"Int J Mol Sci"},{"key":"ref15","doi-asserted-by":"publisher","DOI":"10.3748\/wjg.v24.i27.2974","article-title":"Pathogenesis of non-alcoholic fatty liver disease in children and adolescence: from \"two hit theory\" to \"multiple hit model\"","volume":"24","author":"Fang YL","year":"2018","unstructured":"Fang YL, Chen H, Wang CL, Liang L. Pathogenesis of non-alcoholic fatty liver disease in children and adolescence: from \"two hit theory\" to \"multiple hit model\". World J Gastroenterol. 2018, 24:2974-83. 10.3748\/wjg.v24.i27.2974","journal-title":"World J Gastroenterol"},{"key":"ref16","doi-asserted-by":"publisher","DOI":"10.1016\/j.gtc.2016.07.003","article-title":"Nonalcoholic fatty liver disease: pathophysiology and management","volume":"45","author":"Carr RM","year":"2016","unstructured":"Carr RM, Oranu A, Khungar V. Nonalcoholic fatty liver disease: pathophysiology and management. Gastroenterol Clin North Am. 2016, 45:639-52. 10.1016\/j.gtc.2016.07.003","journal-title":"Gastroenterol Clin North Am"},{"key":"ref17","doi-asserted-by":"publisher","DOI":"10.3390\/ijms21155214","article-title":"Gut microbiota metabolites in NAFLD pathogenesis and therapeutic implications","volume":"21","author":"Chen J","year":"2020","unstructured":"Chen J, Vitetta L. Gut microbiota metabolites in NAFLD pathogenesis and therapeutic implications. Int J Mol Sci. 2020, 21:5214. 10.3390\/ijms21155214","journal-title":"Int J Mol Sci"},{"key":"ref18","doi-asserted-by":"publisher","DOI":"10.1172\/JCI23621","article-title":"Sources of fatty acids stored in liver and secreted via lipoproteins in patients with nonalcoholic fatty liver disease","volume":"115","author":"Donnelly KL","year":"2005","unstructured":"Donnelly KL, Smith CI, Schwarzenberg SJ, Jessurun J, Boldt MD, Parks EJ. Sources of fatty acids stored in liver and secreted via lipoproteins in patients with nonalcoholic fatty liver disease. J Clin Invest. 2005, 115:1343-51. 10.1172\/JCI23621","journal-title":"J Clin Invest"},{"key":"ref19","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2019.06.021","article-title":"The global epidemiology of NAFLD and NASH in patients with type 2 diabetes: a systematic review and meta-analysis","volume":"71","author":"Younossi ZM","year":"2019","unstructured":"Younossi ZM, Golabi P, de Avila L, et al.. The global epidemiology of NAFLD and NASH in patients with type 2 diabetes: a systematic review and meta-analysis. J Hepatol. 2019, 71:793-801. 10.1016\/j.jhep.2019.06.021","journal-title":"J Hepatol"},{"key":"ref20","doi-asserted-by":"publisher","DOI":"10.3390\/ijms21113863","article-title":"The role of insulin resistance and diabetes in nonalcoholic fatty liver disease","volume":"21","author":"Fujii H","year":"2020","unstructured":"Fujii H, Kawada N, Japan Study Group of NAFLD (JSG-NAFLD). The role of insulin resistance and diabetes in nonalcoholic fatty liver disease. Int J Mol Sci. 2020, 21:3863. 10.3390\/ijms21113863","journal-title":"Int J Mol Sci"},{"key":"ref21","doi-asserted-by":"publisher","DOI":"10.1053\/j.gastro.2016.01.025","article-title":"Inflammation in alcoholic and nonalcoholic fatty liver disease: friend or foe?","volume":"150","author":"Gao B","year":"2016","unstructured":"Gao B, Tsukamoto H. Inflammation in alcoholic and nonalcoholic fatty liver disease: friend or foe?. Gastroenterology. 2016, 150:1704-9. 10.1053\/j.gastro.2016.01.025","journal-title":"Gastroenterology"},{"key":"ref22","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhepr.2019.02.004","article-title":"Macrophages in obesity and non-alcoholic fatty liver disease: crosstalk with metabolism","volume":"1","author":"Lefere S","year":"2019","unstructured":"Lefere S, Tacke F. Macrophages in obesity and non-alcoholic fatty liver disease: crosstalk with metabolism. JHEP Rep. 2019, 1:30-43. 10.1016\/j.jhepr.2019.02.004","journal-title":"JHEP Rep"},{"key":"ref23","doi-asserted-by":"publisher","DOI":"10.1038\/srep09589","article-title":"Fructose decreases physical activity and increases body fat without affecting hippocampal neurogenesis and learning relative to an isocaloric glucose diet","volume":"5","author":"Rendeiro C","year":"2015","unstructured":"Rendeiro C, Masnik AM, Mun JG, et al.. Fructose decreases physical activity and increases body fat without affecting hippocampal neurogenesis and learning relative to an isocaloric glucose diet. Sci Rep. 2015, 5:9589. 10.1038\/srep09589","journal-title":"Sci Rep"},{"key":"ref24","doi-asserted-by":"publisher","DOI":"10.3390\/nu9030230","article-title":"Fructose and NAFLD: the multifaceted aspects of fructose metabolism","volume":"9","author":"Jegatheesan P","year":"2017","unstructured":"Jegatheesan P, De Bandt JP. Fructose and NAFLD: the multifaceted aspects of fructose metabolism. Nutrients. 2017, 9:230. 10.3390\/nu9030230","journal-title":"Nutrients"},{"key":"ref25","doi-asserted-by":"publisher","DOI":"10.1136\/gutjnl-2012-303816","article-title":"Intestinal microbiota determines development of non-alcoholic fatty liver disease in mice","volume":"62","author":"Le Roy T","year":"2013","unstructured":"Le Roy T, Llopis M, Lepage P, et al.. Intestinal microbiota determines development of non-alcoholic fatty liver disease in mice. Gut. 2013, 62:1787-94. 10.1136\/gutjnl-2012-303816","journal-title":"Gut"},{"key":"ref26","doi-asserted-by":"publisher","DOI":"10.3390\/nu9111220","article-title":"Nonalcoholic fatty liver disease is exacerbated in high-fat diet-fed gnotobiotic mice by colonization with the gut microbiota from patients with nonalcoholic steatohepatitis","volume":"9","author":"Chiu CC","year":"2017","unstructured":"Chiu CC, Ching YH, Li YP, et al.. Nonalcoholic fatty liver disease is exacerbated in high-fat diet-fed gnotobiotic mice by colonization with the gut microbiota from patients with nonalcoholic steatohepatitis. Nutrients. 2017, 9:1220. 10.3390\/nu9111220","journal-title":"Nutrients"},{"key":"ref27","doi-asserted-by":"publisher","DOI":"10.1016\/j.clcc.2018.05.001","article-title":"Inflammation-modulating effect of butyrate in the prevention of colon cancer by dietary fiber","volume":"17","author":"Chen J","year":"2018","unstructured":"Chen J, Vitetta L. Inflammation-modulating effect of butyrate in the prevention of colon cancer by dietary fiber. Clin Colorectal Cancer. 2018, 17:e541-4. 10.1016\/j.clcc.2018.05.001","journal-title":"Clin Colorectal Cancer"},{"key":"ref28","doi-asserted-by":"publisher","DOI":"10.1111\/apt.15916","article-title":"Systematic review with meta-analysis: liver manifestations and outcomes in COVID-19","volume":"52","author":"Kulkarni AV","year":"2020","unstructured":"Kulkarni AV, Kumar P, Tevethia HV, et al.. Systematic review with meta-analysis: liver manifestations and outcomes in COVID-19. Aliment Pharmacol Ther. 2020, 52:584-99. 10.1111\/apt.15916","journal-title":"Aliment Pharmacol Ther"},{"key":"ref29","doi-asserted-by":"publisher","DOI":"10.1016\/j.prp.2021.153451","article-title":"Liver histopathology in COVID-19 patients: a mono-institutional series of liver biopsies and autopsy specimens","volume":"221","author":"Fassan M","year":"2021","unstructured":"Fassan M, Mescoli C, Sbaraglia M, et al.. Liver histopathology in COVID-19 patients: a mono-institutional series of liver biopsies and autopsy specimens. Pathol Res Pract. 2021, 221:153451. 10.1016\/j.prp.2021.153451","journal-title":"Pathol Res Pract"},{"key":"ref30","doi-asserted-by":"publisher","DOI":"10.3748\/wjg.v26.i48.7693","article-title":"High prevalence of hepatic steatosis and vascular thrombosis in COVID-19: a systematic review and meta-analysis of autopsy data","volume":"26","author":"D\u00edaz LA","year":"2020","unstructured":"D\u00edaz LA, Idalsoaga F, Cannistra M, et al.. High prevalence of hepatic steatosis and vascular thrombosis in COVID-19: a systematic review and meta-analysis of autopsy data. World J Gastroenterol. 2020, 26:7693-706. 10.3748\/wjg.v26.i48.7693","journal-title":"World J Gastroenterol"},{"key":"ref31","doi-asserted-by":"publisher","DOI":"10.1002\/hep.31326","article-title":"Liver biochemistries in hospitalized patients with COVID-19","volume":"73","author":"Bloom PP","year":"2021","unstructured":"Bloom PP, Meyerowitz EA, Reinus Z, et al.. Liver biochemistries in hospitalized patients with COVID-19. Hepatology. 2021, 73:890-900. 10.1002\/hep.31326","journal-title":"Hepatology"},{"key":"ref32","doi-asserted-by":"publisher","DOI":"10.1007\/s13238-020-00718-6","article-title":"Recapitulation of SARS-CoV-2 infection and cholangiocyte damage with human liver ductal organoids","volume":"11","author":"Zhao B","year":"2020","unstructured":"Zhao B, Ni C, Gao R, et al.. Recapitulation of SARS-CoV-2 infection and cholangiocyte damage with human liver ductal organoids. Protein Cell. 2020, 11:771-5. 10.1007\/s13238-020-00718-6","journal-title":"Protein Cell"},{"key":"ref33","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejim.2020.05.035","article-title":"Hepatic consequences of COVID-19 infection. Lapping or biting?","volume":"77","author":"Portincasa P","year":"2020","unstructured":"Portincasa P, Krawczyk M, Machill A, Lammert F, Di Ciaula A. Hepatic consequences of COVID-19 infection. Lapping or biting?. Eur J Intern Med. 2020, 77:18-24. 10.1016\/j.ejim.2020.05.035","journal-title":"Eur J Intern Med"},{"key":"ref34","doi-asserted-by":"publisher","DOI":"10.1097\/MCG.0000000000001481","article-title":"COVID-19 in chronic liver disease and liver transplantation: a clinical review","volume":"55","author":"Mohammed A","year":"2021","unstructured":"Mohammed A, Paranji N, Chen PH, Niu B. COVID-19 in chronic liver disease and liver transplantation: a clinical review. J Clin Gastroenterol. 2021, 55:187-94. 10.1097\/MCG.0000000000001481","journal-title":"J Clin Gastroenterol"},{"key":"ref35","doi-asserted-by":"publisher","DOI":"10.1136\/gut.2004.062398","article-title":"Chronic liver injury in rats and humans upregulates the novel enzyme angiotensin converting enzyme 2","volume":"54","author":"Paizis G","year":"2005","unstructured":"Paizis G, Tikellis C, Cooper ME, et al.. Chronic liver injury in rats and humans upregulates the novel enzyme angiotensin converting enzyme 2. Gut. 2005, 54:1790-6. 10.1136\/gut.2004.062398","journal-title":"Gut"},{"key":"ref36","doi-asserted-by":"publisher","DOI":"10.1038\/s41564-020-0688-y","article-title":"Functional assessment of cell entry and receptor usage for SARS-CoV-2 and other lineage B betacoronaviruses","volume":"5","author":"Letko M","year":"2020","unstructured":"Letko M, Marzi A, Munster V. Functional assessment of cell entry and receptor usage for SARS-CoV-2 and other lineage B betacoronaviruses. Nat Microbiol. 2020, 5:562-9. 10.1038\/s41564-020-0688-y","journal-title":"Nat Microbiol"},{"key":"ref37","doi-asserted-by":"publisher","DOI":"10.1038\/s41392-020-0184-0","article-title":"The role of furin cleavage site in SARS-CoV-2 spike protein-mediated membrane fusion in the presence or absence of trypsin","volume":"5","author":"Xia S","year":"2020","unstructured":"Xia S, Lan Q, Su S, et al.. The role of furin cleavage site in SARS-CoV-2 spike protein-mediated membrane fusion in the presence or absence of trypsin. Signal Transduct Target Ther. 2020, 5:92. 10.1038\/s41392-020-0184-0","journal-title":"Signal Transduct Target Ther"},{"key":"ref38","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(20)30183-5","article-title":"Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China","volume":"395","author":"Huang C","year":"2020","unstructured":"Huang C, Wang Y, Li X, et al.. Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. Lancet. 2020, 395:497-506. 10.1016\/S0140-6736(20)30183-5","journal-title":"Lancet"},{"key":"ref39","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2020.04.006","article-title":"COVID-19: abnormal liver function tests","volume":"73","author":"Cai Q","year":"2020","unstructured":"Cai Q, Huang D, Yu H, et al.. COVID-19: abnormal liver function tests. J Hepatol. 2020, 73:566-74. 10.1016\/j.jhep.2020.04.006","journal-title":"J Hepatol"},{"key":"ref40","doi-asserted-by":"publisher","DOI":"10.3390\/cells10082072","article-title":"Feedback signaling between cholangiopathies, ductular reaction, and non-alcoholic fatty liver disease","volume":"10","author":"Zhou T","year":"2021","unstructured":"Zhou T, Kundu D, Robles-Linares J, et al.. Feedback signaling between cholangiopathies, ductular reaction, and non-alcoholic fatty liver disease. Cells. 2021, 10:2072. 10.3390\/cells10082072","journal-title":"Cells"},{"key":"ref41","doi-asserted-by":"publisher","DOI":"10.1038\/srep31829","article-title":"Simple steatosis sensitizes cholestatic rats to liver injury and dysregulates bile salt synthesis and transport","volume":"6","author":"Lionarons DA","year":"2016","unstructured":"Lionarons DA, Heger M, van Golen RF, et al.. Simple steatosis sensitizes cholestatic rats to liver injury and dysregulates bile salt synthesis and transport. Sci Rep. 2016, 6:31829. 10.1038\/srep31829","journal-title":"Sci Rep"},{"key":"ref42","doi-asserted-by":"publisher","DOI":"10.1111\/1751-2980.12851","article-title":"2019 Novel coronavirus infection and gastrointestinal tract","volume":"21","author":"Gao QY","year":"2020","unstructured":"Gao QY, Chen YX, Fang JY. 2019 Novel coronavirus infection and gastrointestinal tract. J Dig Dis. 2020, 21:125-6. 10.1111\/1751-2980.12851","journal-title":"J Dig Dis"},{"key":"ref43","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbadis.2020.165753","article-title":"Chemical hypoxia induces pro-inflammatory signals in fat-laden hepatocytes and contributes to cellular crosstalk with Kupffer cells through extracellular vesicles","volume":"1866","author":"Hern\u00e1ndez A","year":"2020","unstructured":"Hern\u00e1ndez A, Geng Y, Sep\u00falveda R, et al.. Chemical hypoxia induces pro-inflammatory signals in fat-laden hepatocytes and contributes to cellular crosstalk with Kupffer cells through extracellular vesicles. Biochim Biophys Acta Mol Basis Dis. 2020, 1866:165753. 10.1016\/j.bbadis.2020.165753","journal-title":"Biochim Biophys Acta Mol Basis Dis"},{"key":"ref44","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2021.635471","article-title":"Microbiota modulation of the gut-lung axis in COVID-19","volume":"12","author":"de Oliveira GL","year":"2021","unstructured":"de Oliveira GL, Oliveira CN, Pinzan CF, de Salis LV, Cardoso CR. Microbiota modulation of the gut-lung axis in COVID-19. Front Immunol. 2021, 12:635471. 10.3389\/fimmu.2021.635471","journal-title":"Front Immunol"},{"key":"ref45","doi-asserted-by":"publisher","DOI":"10.1128\/mBio.03022-20","article-title":"Do an altered gut microbiota and an associated leaky gut affect COVID-19 severity?","volume":"12","author":"Kim HS","year":"2021","unstructured":"Kim HS. Do an altered gut microbiota and an associated leaky gut affect COVID-19 severity?. mBio. 2021, 12:1. 10.1128\/mBio.03022-20","journal-title":"mBio"},{"key":"ref46","doi-asserted-by":"publisher","DOI":"10.3389\/fcimb.2020.575559","article-title":"Coronavirus disease (COVID-19) caused by (SARS-CoV-2) infections: a real challenge for human gut microbiota","volume":"10","author":"Vodnar DC","year":"2020","unstructured":"Vodnar DC, Mitrea L, Teleky BE, Szabo K, C\u0103linoiu LF, Neme\u015f SA, Mart\u0103u GA. Coronavirus disease (COVID-19) caused by (SARS-CoV-2) infections: a real challenge for human gut microbiota. Front Cell Infect Microbiol. 2020, 10:575559. 10.3389\/fcimb.2020.575559","journal-title":"Front Cell Infect Microbiol"},{"key":"ref47","doi-asserted-by":"publisher","DOI":"10.1053\/j.gastro.2020.05.048","article-title":"Alterations in gut microbiota of patients with COVID-19 during time of hospitalization","volume":"159","author":"Zuo T","year":"2020","unstructured":"Zuo T, Zhang F, Lui GC, et al.. Alterations in gut microbiota of patients with COVID-19 during time of hospitalization. Gastroenterology. 2020, 159:944-955.e8. 10.1053\/j.gastro.2020.05.048","journal-title":"Gastroenterology"},{"key":"ref48","doi-asserted-by":"publisher","DOI":"10.1053\/j.gastro.2020.02.055","article-title":"Evidence for gastrointestinal infection of SARS-CoV-2","volume":"158","author":"Xiao F","year":"2020","unstructured":"Xiao F, Tang M, Zheng X, Liu Y, Li X, Shan H. Evidence for gastrointestinal infection of SARS-CoV-2. Gastroenterology. 2020, 158:1831-1833.e3. 10.1053\/j.gastro.2020.02.055","journal-title":"Gastroenterology"},{"key":"ref49","doi-asserted-by":"publisher","DOI":"10.1136\/gutjnl-2020-323020","article-title":"Gut microbiota composition reflects disease severity and dysfunctional immune responses in patients with COVID-19","volume":"70","author":"Yeoh YK","year":"2021","unstructured":"Yeoh YK, Zuo T, Lui GC, et al.. Gut microbiota composition reflects disease severity and dysfunctional immune responses in patients with COVID-19. Gut. 2021, 70:698-706. 10.1136\/gutjnl-2020-323020","journal-title":"Gut"},{"key":"ref50","doi-asserted-by":"publisher","DOI":"10.1016\/j.jgg.2021.04.002","article-title":"Gut microbiota, inflammation, and molecular signatures of host response to infection","volume":"48","author":"Gou W","year":"2021","unstructured":"Gou W, Fu Y, Yue L, et al.. Gut microbiota, inflammation, and molecular signatures of host response to infection. J Genet Genomics. 2021, 48:792-802. 10.1016\/j.jgg.2021.04.002","journal-title":"J Genet Genomics"},{"key":"ref51","doi-asserted-by":"publisher","DOI":"10.1136\/gutjnl-2021-324090","article-title":"Six-month follow-up of gut microbiota richness in patients with COVID-19","volume":"71","author":"Chen Y","year":"2022","unstructured":"Chen Y, Gu S, Chen Y, et al.. Six-month follow-up of gut microbiota richness in patients with COVID-19. Gut. 2022, 71:222-5. 10.1136\/gutjnl-2021-324090","journal-title":"Gut"},{"key":"ref52","doi-asserted-by":"publisher","DOI":"10.1016\/j.cpcardiol.2021.100907","article-title":"Alterations of lipid profile in COVID-19: a narrative review","volume":"47","author":"Rezaei A","year":"2022","unstructured":"Rezaei A, Neshat S, Heshmat-Ghahdarijani K. Alterations of lipid profile in COVID-19: a narrative review. Curr Probl Cardiol. 2022, 47:100907. 10.1016\/j.cpcardiol.2021.100907","journal-title":"Curr Probl Cardiol"},{"key":"ref53","doi-asserted-by":"publisher","DOI":"10.3389\/fpubh.2021.705916","article-title":"Cholesterol and triglyceride concentrations, COVID-19 severity, and mortality: a systematic review and meta-analysis with meta-regression","volume":"9","author":"Zinellu A","year":"2021","unstructured":"Zinellu A, Paliogiannis P, Fois AG, Solidoro P, Carru C, Mangoni AA. Cholesterol and triglyceride concentrations, COVID-19 severity, and mortality: a systematic review and meta-analysis with meta-regression. Front Public Health. 2021, 9:705916. 10.3389\/fpubh.2021.705916","journal-title":"Front Public Health"},{"key":"ref54","doi-asserted-by":"publisher","DOI":"10.26355\/eurrev_202003_20706","article-title":"Clinical efficacy of lopinavir\/ritonavir in the treatment of coronavirus disease 2019","volume":"24","author":"Ye XT","year":"2020","unstructured":"Ye XT, Luo YL, Xia SC, et al.. Clinical efficacy of lopinavir\/ritonavir in the treatment of coronavirus disease 2019. Eur Rev Med Pharmacol Sci. 2020, 24:3390-6. 10.26355\/eurrev_202003_20706","journal-title":"Eur Rev Med Pharmacol Sci"},{"key":"ref55","doi-asserted-by":"publisher","DOI":"10.1177\/1756284820959183","article-title":"Tocilizumab and liver injury in patients with COVID-19","volume":"13","author":"Serviddio G","year":"2020","unstructured":"Serviddio G, Villani R, Stallone G, Scioscia G, Foschino-Barbaro MP, Lacedonia D. Tocilizumab and liver injury in patients with COVID-19. Therap Adv Gastroenterol. 2020, 13:10.1177\/1756284820959183","journal-title":"Therap Adv Gastroenterol"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/158413-the-lasting-effects-of-covid-19-on-the-progression-of-metabolic-dysfunction-associated-steatotic-liver-disease-masld","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,2,9]],"date-time":"2024-02-09T20:05:10Z","timestamp":1707509110000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/158413-the-lasting-effects-of-covid-19-on-the-progression-of-metabolic-dysfunction-associated-steatotic-liver-disease-masld"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,9,14]]},"references-count":55,"URL":"https:\/\/doi.org\/10.7759\/cureus.45231","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2023,9,14]]}}}